Literature DB >> 16289139

Comparison of psychic emergence reactions after (+/-)-ketamine and (+)-ketamine in mice.

Jing Liu1, Xing-Quan Ji, Xing-Zu Zhu.   

Abstract

Ketamine is a racemic mixture containing equal parts of (+)-ketamine and (-)-ketamine. The ketamine enantiomorphs are different in anesthesia and psychic emergence reactions after anesthesia. Therefore, (+)-ketamine was compared with racemic ketamine in a number of randomized studies in volunteers and patients. However, their relations remain controversial. In the present studies, the psychic emergence reactions after injection of (+/-)-ketamine and (+)-ketamine were compared in mice. At equimolar doses, the (+)-isomers elicited episodes of hypnosis nearly 1.4-fold more potent than those of the racemic ketamine. After the administration of equihypnotic doses of (+)-ketamine and (+/-)-ketamine, the posthypnotic stimulation of locomotor activity, stereotype behavior and 5-HT-induced head-twitch response by the (+)-enantiomorph was significantly less intense than that of racemic ketamine. In receptor binding test, (+)-ketamine showed a higher affinity for NMDA receptor than that of (+/-)-ketamine, while (+)-ketamine and (+/-)-ketamine showed no affinity for dopamine D2 and serotonin 5-HT2 receptor. These results suggest that the (+)-ketamine has fewer posthypnotic side effects than (+/-)-ketamine when (+)-ketamine and (+/-)-ketamine were administered at equihypnotic dosages and that dopamine D2 and serotonin 5-HT2 receptor were not involved in the effects of (+)-ketamine and (+/-)-ketamine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289139     DOI: 10.1016/j.lfs.2005.08.027

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  Low dose acute alcohol effects on GABA A receptor subtypes.

Authors:  Martin Wallner; H Jacob Hanchar; Richard W Olsen
Journal:  Pharmacol Ther       Date:  2006-07-11       Impact factor: 12.310

2.  Measures of cortical inhibition by paired-pulse transcranial magnetic stimulation in anesthetized rats.

Authors:  Andrew M Vahabzadeh-Hagh; Paul A Muller; Alvaro Pascual-Leone; Frances E Jensen; Alexander Rotenberg
Journal:  J Neurophysiol       Date:  2010-12-15       Impact factor: 2.714

3.  Innovative approaches to treatment - refractory depression: The ketamine story.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

4.  Impact of repeated anesthesia with ketamine and xylazine on the well-being of C57BL/6JRj mice.

Authors:  Katharina Hohlbaum; Bettina Bert; Silke Dietze; Rupert Palme; Heidrun Fink; Christa Thöne-Reineke
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

5.  Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.

Authors:  Fernanda S Correia-Melo; Gustavo C Leal; Michelle S Carvalho; Ana Paula Jesus-Nunes; Carolina B N Ferreira; Flávia Vieira; Guilherme Magnavita; Lucas A S Vale; Rodrigo P Mello; Carolina Nakahira; Felipe C Argolo; Tanise Cardoso; Cezar D S Souza; Ana Teresa C Fontes; Marcelo B Ferreira; Lucas Araújo-de-Freitas; Marco A Tuena; Mariana V F Echegaray; Diogo E Cavalcanti; Ana C Lucchese; Igor D Bandeira; Manuela Telles; Cássio S Lima; Aline S Sampaio; Samantha S Silva; Roberta F Marback; José A Del-Porto; José Neander Abreu; Luciana M Sarin; Camilla S Paixão; Lucas P Carvalho; Paulo R L Machado; Gustavo Turecki; Acioly L T Lacerda; Lucas C Quarantini
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  The antidepressant effect and safety of non-intranasal esketamine: A systematic review.

Authors:  Sanne Y Smith-Apeldoorn; Maurice Vischjager; Jolien Ke Veraart; Jeanine Kamphuis; Marije Aan Het Rot; Robert A Schoevers
Journal:  J Psychopharmacol       Date:  2022-05-12       Impact factor: 4.562

7.  Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.

Authors:  Sanne Y Smith-Apeldoorn; Jolien K E Veraart; Jeanine Kamphuis; Antoinette D I van Asselt; Daan J Touw; Marije Aan Het Rot; Robert A Schoevers
Journal:  BMC Psychiatry       Date:  2019-11-29       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.